13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002018299
Total reported value
$1.3B
$1.3B
20 檔
10.4%
According to the latest 13F quarterly dataset, Boxer Capital Management, LLC managed an equity portfolio of $1.3B at the end of Q2 2025, spanning 20 distinct U.S. exchange-listed positions.
In Q2 2025, Boxer Capital Management, LLC adopted a defensive or profit-taking posture, trimming 7 positions and completely liquidating 16 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics Inc | Stock-Other | 25.18% | -4.26% | -5.87% | |
| 2 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 14.69% | +0.67% | -39.83% | |
| 3 | REPL | Replimune Group Inc | Stock-Other | 10.34% | +2.14% | +23.10% | |
| 4 | ✓ | Merus N V | Stock-Other | 9.66% | — | -47.86% | |
| 5 | KYMR | Kymera Therapeutics Inc | Stock-Other | 9.49% | +0.11% | +32.93% | |
| 6 | QURE | uniQure N.V. | Stock-Other | 6.31% | +3.79% | +19.93% | |
| 7 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 4.14% | — | — | |
| 8 | URGN | UroGen Pharma Ltd. | Stock-Other | 3.97% | +0.21% | — | |
| 9 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 3.95% | -0.38% | -30.00% | |
| 10 | ✓ | Crescent Biopharma Inc. | Stock-Other | 3.69% | — | — | |
| 11 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.67% | -0.78% | — | |
| 12 | NKTR | Nektar Therapeutics | Stock-Other | 1.63% | — | — | |
| 13 | KOD | Kodiak Sciences Inc | Stock-Other | 1.41% | -2.47% | -27.54% | |
| 14 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.35% | — | — | |
| 15 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.00% | -0.02% | -68.92% | |
| 16 | TIL | Instil Bio Inc | Stock-Other | 0.74% | — | -11.76% | |
| 17 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.53% | -0.05% | EXIT | |
| 18 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.22% | -0.23% | — | |
| 19 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.04% | — | — | |
| 20 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics Inc | +20.9% | -5.87% | Trim |
| 2 | KYMR | Kymera Therapeutics Inc | +6.8% | +32.93% | Add |
| 3 | REPL | Replimune Group Inc | +5.1% | +23.10% | Add |
| 4 | QURE | uniQure N.V. | +3.9% | +19.93% | Add |
| 5 | AMLX | Amylyx Pharmaceuticals Inc | +2.1% | -30.00% | Trim |
| 6 | ✓ | Merus N V | +0.8% | -47.86% | Trim |
| 7 | RVMD | Revolution Medicines Inc | +0.7% | -39.83% | Trim |
| 8 | KOD | Kodiak Sciences Inc | +0.5% | -27.54% | Trim |
| 9 | TIL | Instil Bio Inc | +0.3% | -11.76% | Trim |
| 10 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 11 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 12 | NRIX | Nurix Therapeutics Inc | -1% | -68.92% | Trim |
| 13 | NUVL | Nuvalent Inc-a | — | EXIT | Sold out |
| 14 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 15 | ANAB | Anaptysbio Inc | — | EXIT | Sold out |
| 16 | XENE | Xenon Pharmaceuticals Inc | — | EXIT | Sold out |
| 17 | APLSUSD | Apellis Pharmaceuticals Inc | — | EXIT | Sold out |
| 18 | CMRXEUR | Chimerix Inc | — | EXIT | Sold out |
| 19 | ELVN | Enliven Therapeutics Inc | — | EXIT | Sold out |
| 20 | ORIC | Oric Pharmaceuticals Inc | — | EXIT | Sold out |
| 21 | DAWNGBX | Day One Biopharmaceuticals I | — | EXIT | Sold out |
| 22 | PRTA | Prothena Corporation plc | — | EXIT | Sold out |
| 23 | 2662247D | Iteos Therapeutics Inc | — | NEW | New buy |
| 24 | URGN | UroGen Pharma Ltd. | — | NEW | New buy |
| 25 | ✓ | Crescent Biopharma Inc. | — | NEW | New buy |
| 26 | LEGN | Legend Biotech Corp-adr | — | EXIT | Sold out |
| 27 | SLDB | Solid Biosciences Inc | — | EXIT | Sold out |
| 28 | DNLI | Denali Therapeutics Inc | — | EXIT | Sold out |
| 29 | PTGX | Protagonist Therapeutics Inc | — | NEW | New buy |
| 30 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 31 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 32 | PRLD | Prelude Therapeutics Inc | — | EXIT | Sold out |
| 33 | 4XC1 | Kalvista Pharmaceuticals Inc | — | NEW | New buy |
| 34 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 35 | BOLD | Boundless Bio Inc | — | EXIT | Sold out |
| 36 | CLYM | Climb Bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Boxer Capital Management, LLC reported a total U.S. public equity portfolio value of $1.3B across 20 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TNGX, RVMD, REPL) accounted for 10.4% of total reported equity market value during Q2 2025.
Top New Position Initiated
2662247D
市值: $8.2M
Top Position Liquidated / Trimmed
NUVL
前期市值: $31.9M
During Q2 2025, Boxer Capital Management, LLC's top holdings by market value included TNGX (25.2%)、RVMD (14.7%)、REPL (10.3%). The largest single position, TNGX, represented 25.2% of total portfolio value.
In Q2 2025, Boxer Capital Management, LLC made 34 total portfolio adjustments, initiating 8 new buys, adding to 3 positions, trimming 7 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.